Intact Vascular raises $39M in venture capital funding to further develop its Tack Endovascular System

| Printer friendly version

Intact Vascular, Inc. is a Wayne, Pennsylvania-based developer of medical devices for treating patients with peripheral artery disease. According to its website, the privately-held company primarily develops minimally invasive peripheral vascular products, such as the Tack Endovascular System, which is stated to optimize percutaneous balloon angioplasty results in the treatment of peripheral artery disease.

According to a press release, Intact Vascular has raised $38.9 million in a Series B venture capital financing led by New Enterprise Associates (NEA), with participation from Quaker Partners, H.I.G. BioVentures, and other existing investors. NEA Parner Justin Klein, MD, JD, has joined Intact Vascular’s Board of Directors as a result of the deal.

The press release indicates that the funds will be used to further develop and refine the Tack Endovascular System implant and delivery system, which has already been put through three international clinical trials and has resulted in a CE-Mark.

According to Intact Vascular’s website, the Tack Endovascular System is designed to effectively spot treat and repair arterial dissections in peripheral arteries following angioplasty using a minimal metal implant.

tack

Intact Vascular’s website lists several features of the Tack Endovascular System that are purported to be unique. The website indicates that minimal use of metal reduces the amount of foreign material left behind in the body, resulting in reduced inflammation. The design also places less force on the vessel wall, which reduces vessel trauma and reaction. Other stated benefits of the design include allowing physicians to focus treatment only on the areas of the vessel where dissections are present, and allowing for the device to fit a wide range of artery diameters — eliminating the need to precisely size the device to a specific arterial diameter, an improvement over conventional stents.

This Tack Endovascular System has room to make a big impact: peripheral artery disease currently affects more than 200 million people worldwide, and over 19 million people in the U.S., with the numbers increase annually due to obesity, diabetes, and advancing age. However, newly-appointed member of the Board of Directors, Dr. Justin Klein, is optimistic. He states that: “Intact Vascular’s approach to peripheral artery disease is truly novel and has the potential to significantly improve treatment of this rapidly growing disease.”

Only time will tell if the Tack Endovascular System is able to meet this potential.

Show Wang
Show Wang is an associate in our Orange County office. In 2009, Mr. Wang graduated with a degree in Biomedical Engineering from Duke University, where he researched and built low-cost wireless ECG machines. After graduation, Mr. Wang worked at a hedge fund before helping a biomedical startup model the thermal profiles of surgically-implantable cooling chips. While attending law school, Mr. Wang spent some time at the USPTO as an examiner extern. Mr. Wang graduated from New York University School of Law in 2014. Mr. Wang was a summer associate with the firm in 2013, and joined the firm as an associate in 2014.
Click here to read full bio
View all posts published by Show Wang »

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.